Penn Engineers have redesigned a key component of lipid nanoparticles (LNPs), the delivery vehicles behind mRNA vaccines, to steer the particles toward lymph nodes while reducing off-target delivery to the liver. The advance could make mRNA vaccines more efficient, potentially achieving strong immune protection at lower doses.
“The more particles that reach the lymph nodes, the fewer particles each dose needs,” says Michael J. Mitchell, Associate Professor in Bioengineering (BE) and senior author of a new study in Journal of the American Chemical Society that describes how the researchers modified the ionizable lipid, a key LNP ingredient that helps mRNA enter cells.
In animal models, the new “aroLNPs,” whose name refers to the addition of a chemical structure called an “aromatic ring” to the ionizable lipid, delivered at least 10-fold less mRNA to the liver compared to the LNP formulation in the Moderna COVID-19 vaccine, while maintaining similar levels of lymph-node delivery.








